Search by drug, manufacturer, or indication

Displaying 851 - 860 of 1165

Alecensaro (alectinib)

Status:

Concluded with an LOI

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Non-small cell lung cancer (NSCLC), locally advanced or metastatic

Last updated December 11, 2018

Gazyva (obinutuzumab)

Status:

Negotiations were not pursued

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Follicular lymphoma, Relapsed or refractory

Last updated December 7, 2018

Actemra (tocilizumab)

Status:

Concluded with an LOI

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Giant Cell Arteritis

Last updated December 6, 2018

Izba (travoprost)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Open-angle Glaucoma

Last updated December 6, 2018

Ozanex (ozenoxacin)

Status:

Negotiations were not pursued

Manufacturer:

Ferrer Internacional

Indication:

Impetigo

Last updated November 30, 2018

Ozurdex (dexamethasone)

Status:

Negotiations were not pursued

Manufacturer:

Allergan Inc.

Indication:

Diabetic Macular Edema

Last updated November 29, 2018

Nucynta (tapentadol hydrochloride)

Status:

Negotiations were not pursued

Manufacturer:

Paladin Labs Inc.

Indication:

Pain, severe

Last updated November 29, 2018

Tecentriq (atezolizumab)

Status:

Concluded with an LOI

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Non-small Cell Lung Cancer

Last updated November 29, 2018

Copaxone (glatiramer acetate)

Status:

Concluded without agreement

Manufacturer:

Teva Canada Ltd.

Indication:

Clinically Isolated Syndrome

Last updated November 29, 2018

Vimizim (elosulfase alfa)

Status:

Concluded with an LOI

Manufacturer:

BioMarin Pharmaceutical Inc.

Indication:

Mucopolysaccharidosis IVA (Morquio A syndrome)

Last updated November 29, 2018